Clinical trial Recruiting at 1 site Observational Ages 28 Days to 48 Months

Pneumococcal Carriage Duration in Young Children

Official title: NIS103487 Duration of Streptococcus Pneumoniae Carriage in U.S. Children Under Five: A Pilot Longitudinal Study

Run by University of Central Florida · NCT07748832 · Data updated 2026-11-12

This study tests how long Streptococcus pneumoniae stays in the noses/throats of children under 4 who are followed for a year with regular swabs.

Quick facts

Study typeObservational
Ages28 Days to 48 Months
SexAll
Enrollment60 (estimated)
SponsorUniversity of Central Florida
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Orlando, Florida)
StatusRecruiting
StartedJuly 21, 2026
Main results expectedJuly 2027
Study endsJuly 2027
Registry record updatedAugust 6, 2026
Trial IDNCT07748832 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 28 days to under 4 years whose parent/guardian can consent, read English or Spanish, and commit to 12 months of biweekly OP swabs.

Probably not a fit

Children with chronic illnesses or immunocompromising conditions, or those unable to comply with the 12-month sampling schedule, may not benefit from the study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study tracks pneumococcal carriage over 12 months in young children to estimate how long colonization lasts and to explore patterns of co-colonization and interactions with viruses and the respiratory microbiome. High-resolution sampling and genomic methods will be used to generate updated carriage estimates in a U.S. pediatric population. Oropharyngeal swabs are collected biweekly, with caregiver questionnaires to understand factors that may influence carriage. The study aims to inform future pneumococcal vaccine strategies and public health planning.

Why it matters

Potential benefit: If successful, the study could improve understanding of carriage duration and microbial interactions, potentially guiding vaccine development and public health interventions.

How similar studies have gone: Previous studies have used longitudinal sampling and genomic methods to study pneumococcal carriage, supporting the feasibility of this approach in children.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Are older than 28 days and under 4 years of age at the time of enrollment.
* Have a parent or legal guardian who:

  1. Provides written informed consent.
  2. Is able to read and speak English or Spanish.
  3. Agrees to comply with all study procedures, including completion of questionnaires and biweekly oropharyngeal (OP) swab collections from the child for a period of 12 months.

Exclusion Criteria:

* History of chronic medical conditions or immunocompromising conditions that may influence pneumococcal carriage or study participation, such as:
* cystic fibrosis
* cerebral palsy
* neuromuscular disorders
* congenital heart disease
* known congenital or acquired immunodeficiencies
* sickle cell disease
* undergoing immunosuppressive therapy (e.g., systemic corticosteroids ≥2 mg/kg/day for ≥14 days, chemotherapy, biologics)

Where it's running

  • University of Central Florida
    Orlando, Florida, United States
    Recruiting

Study contacts

  • Principal investigator: Dr. Taj Azarian, PhD — University of Central Florida
  • Study coordinator: Dr. Amoy Fraser, PhD
  • Email: Amoy.Fraser@UCF.edu
  • Phone: 407-266-8742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.